Thought Leadership
Email Page
Legal Opinion: BPCIA is Likely to Survive Latest ACA Challenge
November 11, 2020
Chad Landmon and Drew Hillier
The Center for Biosimilars

Axinn partner Chad Landmon and associate Drew Hillier authored The Center for Biosimilars article, "Legal Opinion: BPCIA is Likely to Survive Latest ACA Challenge." 

Click here to access the article.

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.